Illustration: Gabriella Turrisi/Axios
Rumors of an AstraZeneca-Bristol Myers Squibb deal seemed at odds with investors' emerging preference for targeted growth assets.
The big picture: Big Pharma has increasingly been funneling money into bolt-on acquisitions rather than megadeals.
